title: CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy.
abstract: We report the clinical and radiological central nervous system (CNS) findings of 8 Fabry disease patients, before (8/8) and after (7/8) 12 months of enzyme replacement therapy (ERT) with agalsidase-alpha. Eight biochemically proven Fabry disease patients (from four families) were included. Patients were evaluated at baseline and at regular intervals during 12 months of ERT. Evaluations included a thorough, standardized neurological examination, and magnetic resonance imaging (MRI) and angiography (MRA). Brain proton magnetic resonance spectroscopy (MRS) was also performed in 5/8 patients. The presence and location of grey- and white-matter lesions, the presence of vascular occlusion or ectasia on MRA and the metabolite ratios on MRS were determined, as well as their relation to age, symptoms and neurological examination. Neurological examination showed few abnormalities in these patients: scores varied (on a 0-100 scale) from zero to 5, at baseline and in the 12th month of ERT. The most consistent findings on MRI were asymmetric, widespread patterns of deep white-matter (WM) lesions, hyperintense on T2 and FLAIR-weighted images, found in 4/8 patients at baseline, predominantly in frontal and parietal lobes. These lesions did not correlate with other clinical variables, although there was a trend towards an association of the lesions with age and hearing loss. The youngest patient with MRI lesions was 24 years old. After 12 months of ERT, MRI was normal in 3/7, showed the same WM lesions in 2/7, and showed worsening of WM lesions in 2/7 patients (from the same family). Abnormal MRS metabolite ratios were detected at baseline in 4/5 patients. While neurological examination remained almost normal during the 12 months of ERT, new small-vessel CNS involvement still appeared in 2/7 patients. We do not know why ERT was not able to prevent this in these two related male patients. This could be due either to their older ages (46 and 36 years), or to a more pathogenic mutation. We conclude that MRI was more sensitive than neurological examination in detecting CNS involvement and progression in Fabry disease in the time interval studied.
authors.affiliation: Medical Genetics Service, Hospital de Clinicas de Porto Alegre, Rua Ramiro Barcelos 2350, 90.035-003 Porto Alegre, Brazil. laurajardim@terra.com.br
authors.forename: L
authors.initials: L
authors.lastname: Jardim
authors.forename: L
authors.initials: L
authors.lastname: Vedolin
authors.forename: I V D
authors.initials: IV
authors.lastname: Schwartz
authors.forename: M G
authors.initials: MG
authors.lastname: Burin
authors.forename: C
authors.initials: C
authors.lastname: Cecchin
authors.forename: L
authors.initials: L
authors.lastname: Kalakun
authors.forename: U
authors.initials: U
authors.lastname: Matte
authors.forename: F
authors.initials: F
authors.lastname: Aesse
authors.forename: C
authors.initials: C
authors.lastname: Pitta-Pinheiro
authors.forename: J
authors.initials: J
authors.lastname: Marconato
authors.forename: R
authors.initials: R
authors.lastname: Giugliani
mesh_terms: D000328:Adult; D001921:Brain / Q000473:pathology*; D015331:Cohort Studies; D018450:Disease Progression; D000795:Fabry Disease / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007527:Isoenzymes / Q000008:administration & dosage*; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D012680:Sensitivity and Specificity; D000519:alpha-Galactosidase / Q000008:administration & dosage*
chemical_list: D007527:Isoenzymes; D000519:alpha-Galactosidase